[go: up one dir, main page]

MX2023001438A - Formulaciones de compuestos calciliticos de trifenilo. - Google Patents

Formulaciones de compuestos calciliticos de trifenilo.

Info

Publication number
MX2023001438A
MX2023001438A MX2023001438A MX2023001438A MX2023001438A MX 2023001438 A MX2023001438 A MX 2023001438A MX 2023001438 A MX2023001438 A MX 2023001438A MX 2023001438 A MX2023001438 A MX 2023001438A MX 2023001438 A MX2023001438 A MX 2023001438A
Authority
MX
Mexico
Prior art keywords
triphenyl
formulations
calcilytic compounds
compound
calcilytic
Prior art date
Application number
MX2023001438A
Other languages
English (en)
Inventor
Uma Sinha
Ali Komeyli
Ananth Sridhar
Leena Prasad
Original Assignee
Calcilytix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calcilytix Therapeutics Inc filed Critical Calcilytix Therapeutics Inc
Publication of MX2023001438A publication Critical patent/MX2023001438A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona formulaciones de tableta que incluyen un compuesto calcilítico de trifenilo para el tratamiento de hipocalcemia autosómica dominante (ADH), donde el compuesto está representado por la fórmula (I): (ver fórmula I), un solvato, un hidrato, una sal farmacéuticamente aceptable, o una combinación de los mismos.
MX2023001438A 2020-08-04 2021-08-03 Formulaciones de compuestos calciliticos de trifenilo. MX2023001438A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061050P 2020-08-04 2020-08-04
PCT/US2021/044295 WO2022031666A1 (en) 2020-08-04 2021-08-03 Formulations of triphenyl calcilytic compounds

Publications (1)

Publication Number Publication Date
MX2023001438A true MX2023001438A (es) 2023-06-15

Family

ID=77431430

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001438A MX2023001438A (es) 2020-08-04 2021-08-03 Formulaciones de compuestos calciliticos de trifenilo.

Country Status (13)

Country Link
US (2) US20220040112A1 (es)
EP (1) EP4192438A1 (es)
JP (1) JP2023536667A (es)
KR (1) KR20230106582A (es)
CN (1) CN116648243A (es)
AR (1) AR123147A1 (es)
AU (1) AU2021320147A1 (es)
BR (1) BR112023002107A2 (es)
CA (1) CA3188044A1 (es)
IL (1) IL300285A (es)
MX (1) MX2023001438A (es)
TW (1) TW202220642A (es)
WO (1) WO2022031666A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4192438A1 (en) 2020-08-04 2023-06-14 Calcilytix Therapeutics, Inc. Formulations of triphenyl calcilytic compounds
US20220087961A1 (en) * 2020-09-18 2022-03-24 Calcilytix Therapeutics, Inc. Treatment methods of triphenyl calcilytic compounds
WO2024160842A1 (en) 2023-01-30 2024-08-08 Medizinische Universität Wien Use of calcilytics for preventing or treating hypoparathyroidism associated with anterior neck surgery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1619180E (pt) 2003-04-23 2009-12-29 Japan Tobacco Inc Antagonista de casr
EP1964548A1 (en) * 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent
NZ595513A (en) * 2009-03-26 2013-05-31 Japan Tobacco Inc Process for producing carboxylic acid compound
DK3150198T3 (da) * 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
GB201217330D0 (en) * 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN117024420A (zh) 2017-12-29 2023-11-10 生物马林药物股份有限公司 用于疾病治疗的乙醇酸氧化酶抑制剂
WO2021029517A1 (en) 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
GB201918586D0 (en) * 2019-12-17 2020-01-29 Patterson James Engineered platelets for targeted delivery of a therapeutic agent
EP4192438A1 (en) 2020-08-04 2023-06-14 Calcilytix Therapeutics, Inc. Formulations of triphenyl calcilytic compounds
US20220087961A1 (en) 2020-09-18 2022-03-24 Calcilytix Therapeutics, Inc. Treatment methods of triphenyl calcilytic compounds

Also Published As

Publication number Publication date
IL300285A (en) 2023-04-01
CN116648243A (zh) 2023-08-25
US20220040112A1 (en) 2022-02-10
AR123147A1 (es) 2022-11-02
US12357576B2 (en) 2025-07-15
US20240074978A1 (en) 2024-03-07
TW202220642A (zh) 2022-06-01
BR112023002107A2 (pt) 2023-03-07
WO2022031666A1 (en) 2022-02-10
AU2021320147A1 (en) 2023-03-30
EP4192438A1 (en) 2023-06-14
CA3188044A1 (en) 2022-02-10
KR20230106582A (ko) 2023-07-13
JP2023536667A (ja) 2023-08-28

Similar Documents

Publication Publication Date Title
CO2024001367A2 (es) Compuestos antivirales
MX2023001438A (es) Formulaciones de compuestos calciliticos de trifenilo.
MX2021011606A (es) Compuestos dirigidos a prmt5.
DOP2023000280A (es) Inhibidores de cdk2
MX2022012240A (es) Metilacion de compuestos mcl-1.
MX2024009943A (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CL2023003758A1 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
MX2024011179A (es) Compuestos multiciclicos
MX2025002817A (es) Compuestos para el tratamiento del cancer
CO2024010726A2 (es) Compuestos heterocíclicos y métodos de uso
DOP2025000009A (es) Inhibidores de acc novedosos
DOP2024000077A (es) Compuestos de cd73
CL2023003253A1 (es) Moduladores de trex1
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
CL2023003168A1 (es) Moduladores de trex1
UY39649A (es) Compuesto para el tratamiento de trastornos cognitivos
CR20240570A (es) Compuestos de cd73
AR128504A1 (es) Compuestos antivirales de pirazolopiridinona
CO2025006324A2 (es) Compuestos tricíclicos
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
AR121716A1 (es) Metilación de compuestos mcl-1
AR128426A1 (es) Compuestos heterocíclicos y métodos de uso
CO2022012616A2 (es) Compuestos de bencimidazol para el tratamiento de trastornos metabólicos